RxDoctor Payments Data

Elizabeth Schaut, PA

Physician Assistant · Chula Vista, CANPI 1629486006

Payments from drug & device makers

$7,056in general payments, 2019–2025

Across 313 payments — averaging $22.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$1K
  • Johnson & Johnson$844
  • AbbVie$820
  • Incyte Corporation$702
  • Sun Pharmaceutical Industries Inc.$533
  • Pfizer$437
  • plus $3K from 19 others

What the payments were for

  • Food & beverage$6,57493%
  • Education$4827%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,056 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$36,158
Medicare patients
103
Services billed
514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab18$64,195
Dupixent SyringeDupilumab17$62,176
OpzeluraRuxolitinib Phosphate14$26,703
ZoryveRoflumilast12$9,754
Tacrolimus59$9,078
Betamethasone Dipropionate175$6,013
Ketoconazole209$3,539
Clindamycin Phosphate59$3,135
Metronidazole44$2,571
Triamcinolone Acetonide84$1,313
Fluorouracil11$728
Tretinoin12$655
Doxycycline Hyclate23$542
Mometasone Furoate14$349
Ciclopirox29$348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$702$26,70314 claims
Arcutis Biotherapeutics, Inc.Zoryve$372$9,75412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Chula Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →